I'll make it even easier for you then.
Here is a simpler version:
Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19:
Preliminary results from a multi-centre, randomized, controlled trial.
Running title: Hydroxychloroquine for COVID-19 – Preliminary Report
RECOVERY Collaborative Group*https://www.medrxiv.org/content/10.1101/2020.07.15.20151852v1.full.pdfEligible and consenting patients were
111 assigned in a ratio of 2:1 to either usual standard of care or usual standard of care plus
112 hydroxychloroquine or one of the other available treatment arms (see Supplementary Appendix)
113 using web-based simple (unstratified) randomization with allocation concealment. Patients
114 allocated to hydroxychloroquine sulfate (200mg tablet containing 155mg base equivalent)
115 received a loading dose of 4 tablets (800 mg) at zero and 6 hours, followed by 2 tablets (400
116 mg) starting at 12 hours after the initial dose and then every 12 hours for the next 9 days or until
discharge (whichever occurred earlier) (see Supplementary Appendix).
15 117 Allocated treatment
118 was prescribed by the attending clinician. Participants and local study staff were not blinded to
119 the allocated treatment.
Apologies for the formatting. but that's just how it came out.
If the trial protocol doesn't meet your exacting standards (based on your own extensive medico-scientific qualifications), I've already provided you the link to the NIH site, where you can submit your objection.
Be sure to explain to them why your qualifications are superior to those of:
| Principal Investigator: Peter W Horby |
| Principal Investigator: Martin Landray |
| Principal Investigator: Wei Shen Lim |
| Principal Investigator: Kenneth Baillie |
| Principal Investigator: Richard Haynes |
| Principal Investigator: Ed Juszczak |
| Principal Investigator: Thomas Jaki |
Please keep us apprised of any response they send back to you.
.
